{"DataElement":{"publicId":"12100431","version":"1","preferredName":"Hormone Therapy Planned Category Code","preferredDefinition":"The code that represents the name of the agent used in the planned treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","longName":"2553528v1.00:12100422v1.00","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"2553528","version":"1","preferredName":"Hormone Therapy Planned","preferredDefinition":"information related to the planned hormone therapy to be administered.","longName":"HORMTX_PLAN","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2433915","version":"1","preferredName":"Hormone Therapy","preferredDefinition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.","longName":"C15445","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CDA8-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2475238","version":"1","preferredName":"Planned","preferredDefinition":"Planned; devised, contrived, or formed in design.","longName":"C25619","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plan","conceptCode":"C25619","definition":"To devise, contrive, or form in design.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11A2D427-7660-5E1B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-17","modifiedBy":"ONEDATA","dateModified":"2006-04-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24924F4F-ED80-4F3E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-12-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"12100422","version":"1","preferredName":"Category Code","preferredDefinition":"A grouping of items based on some commonality or by user defined characteristics._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"12100422v1.00","context":"SWOG","contextVersion":"1","type":"Enumerated","dataType":"ALPHANUMERIC","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"1","valueDescription":null,"ValueMeaning":{"publicId":"12100425","version":"1","preferredName":"Tamoxifen","longName":"12100425v1.00","preferredDefinition":"An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen","conceptCode":"C62078","definition":"An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDC2227D-5488-7F4E-E053-731AD00A2C2D","latestVersionIndicator":"Yes","beginDate":"2022-11-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-11-18","modifiedBy":"SOKKERL","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDC2227D-5489-7F4E-E053-731AD00A2C2D","beginDate":"2022-11-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-11-18","modifiedBy":"SOKKERL","dateModified":"2022-11-18","deletedIndicator":"No"},{"value":"2","valueDescription":null,"ValueMeaning":{"publicId":"2897676","version":"1","preferredName":"Aromatase Inhibitor","longName":"2897676","preferredDefinition":"An agent that blocks the function of the enzyme aromatase with antineoplastic activity.  Aromatase inhibitors belong to two classes: Type I steroidal drugs are androgen substrate analogues that bind competitively but irreversibly to the enzyme.  Type II nonsteroidal inhibitors fit into the substrate binding site and bind reversibly to the enzyme.  Present in many tissues, aromatases are heme-containing enzymes that catalyze the adrenal conversion of cholesterol to pregnenolone and the peripheral conversion (aromatization) of androgenic precursors to estrogens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aromatase Inhibitor","conceptCode":"C1740","definition":"Any substance that inhibits aromatase, an enzyme responsible for the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. Inhibition of aromatase results in the suppression of estrogen-regulated processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B75B6A8-FB4E-BC7B-E040-BB89AD4323EC","latestVersionIndicator":"Yes","beginDate":"2009-06-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-06-03","modifiedBy":"FINCHAMB","dateModified":"2022-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDC2227D-548A-7F4E-E053-731AD00A2C2D","beginDate":"2022-11-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-11-18","modifiedBy":"SOKKERL","dateModified":"2022-11-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5655898","version":"1","preferredName":"Category Code","preferredDefinition":"A grouping of items based on some commonality or by user defined characteristics.:A symbol or combination of symbols which is assigned to the members of a collection.","longName":"C25372:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"480624CD-3718-76E2-E053-F662850A36F5","latestVersionIndicator":"Yes","beginDate":"2017-02-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-02-08","modifiedBy":"ONEDATA","dateModified":"2017-02-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDC21786-5AAF-7DFE-E053-731AD00AEA1F","latestVersionIndicator":"Yes","beginDate":"2022-11-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-11-18","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What is the category of planned oral endocrine therapy for this participant while on study?","url":null,"context":"SWOG"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDC267D0-9835-117D-E053-731AD00A1552","latestVersionIndicator":"Yes","beginDate":"2022-11-18","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2022-11-18","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}